Breelyn Wilky update

Trials for Anti-PD-1 or anti-PD-L1 antibodies with participating ASPS patients
Post Reply
D.ap
Senior Member
Posts: 4096
Joined: Fri Jan 18, 2013 11:19 am

Breelyn Wilky update

Post by D.ap »

Debbie
D.ap
Senior Member
Posts: 4096
Joined: Fri Jan 18, 2013 11:19 am

Re: Breelyn Wilky update

Post by D.ap »

Dr. Wilky on Pembrolizumab Plus Axitinib in Sarcoma
Debbie
D.ap
Senior Member
Posts: 4096
Joined: Fri Jan 18, 2013 11:19 am

Axitinib/Pembrolizumab Shows Promising Results in Alveolar Soft-Part Sarcoma

Post by D.ap »

Final paragraph-



"Wilky said these results are promising, and the study has expanded and will include 10 more ASPS patients to confirm the combination’s efficacy in this subtype. She added that future clinical trials should include validation of clinical biomarkers of response to immune therapy"


http://www.cancernetwork.com/ctos-2017/ ... rt-sarcoma
Debbie
D.ap
Senior Member
Posts: 4096
Joined: Fri Jan 18, 2013 11:19 am

axitinib-and-pembrolizumab-in-advanced-renal-cell-cancer

Post by D.ap »

Debbie
Olga
Admin
Posts: 2349
Joined: Mon Jun 26, 2006 11:46 pm
Location: Vancouver, Canada

Re: Breelyn Wilky update

Post by Olga »

Deb, I am not sure why are you posting the last years updates? I am expecting that there should be the final results soon or some additional results up to date from this trial.
Also Brittany Sullivan blog does not have any updates since the last Feb or so I was wondering what is going on with her after she was taken off the trial due to rheumatic side effects. Lots of spammers posted after her last post too, sad to see. If you have her personal contacts, let her know.
Olga
D.ap
Senior Member
Posts: 4096
Joined: Fri Jan 18, 2013 11:19 am

Re: Breelyn Wilky update

Post by D.ap »

Olga
Just trying to bump this post and found additional info while looking for current updates .
Debbie
D.ap
Senior Member
Posts: 4096
Joined: Fri Jan 18, 2013 11:19 am

Re: Breelyn Wilky update

Post by D.ap »

Twitter

Began with

“Combinations are already there @SylvesterCancer ! Response rates are higher with axitinib + pembrolizumab. Seems this is more likely to be the new standard of care for #ASPS #sarcoma as presented @ASCO @breelynwilky @VaiaFlorou @ConquerCancerFd ascopubs.org/doi/abs/10.120…”

Response from Breelyn to Jon Rosenberg

“Another interesting tidbit from Rosenberg at #SITC2018 was that many hotspot mutations in p53 can produce immunogenic neoantigens recognizable by TIL therapy- gives hope for immunotherapy for p53 which is so common in sarcomas.”


Breelyn at univesary of Colorado
P53
Linked to—

https://m.medicalxpress.com/news/2018-1 ... rdian.html

Good sarcoma folks on our side ! : )
Debbie
Post Reply

Return to “Immune checkpoint inhibitors (ICI)”